Low dose reirradiation in combination with hyperthermia: A palliative treatment for patients with breast cancer recurring in previously irradiated areas

Zee, Jacoba van der; Treurniet-Donker, A. D.; The, S.; Helle, P.A.; Seldenrath, J.J.; Meerwaldt, J.H.; Wijnmaalen, Arendjan; Berg, A. P. Van Den; Rhoon, Gerard C. van; Broekmeyer-Reurink, M. P.; Reinhold, H

doi:10.1016/0360-3016(88)90237-4

Cited by 72 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With RT alone at doses of 30Ð40 Gy, CR rates varying from 20% to 48% have been reported for breast cancer (van der Zee and Vernon, 1996). The same RT schedule of eight fractions of 4 Gy without HT has been applied in the RTOG 81-04 study, resulting in overall 26% complete response (Perez et al, 1989).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation

et al. 1999

View full text Add to dashboard Cite

Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71%. Including the 15 patients with microscopic disease, the local control rate was 73%. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas. © 1999 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 99%

“…During treatment, patients were instructed to report pain immediately; in fact this Ôsubjective thermometryÕ is a very important parameter in treatment control and should not be considered a side-effect of HT. The interstitial catheters for thermometry generally do not cause relevant problems (van der Zee et al, 1987).…”

Section: Discussionmentioning

confidence: 99%

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Hyperthermia (HT) refers to heat treatment of cancer cells or tumours by increasing the temperature to a level between 39 and 45˚C. It is used in combination with chemo-and/or radiotherapy and it is has been shown to enhance their anticancer effects experimentally and clinically (12)(13)(14)(15)(16). A number of in vitro studies on the combination of HT and radiation have demonstrated a synergistic interaction between the two modalities, particularly at higher temperatures (>42˚C) (17)(18)(19).…”

Section: Hyperthermiamentioning

confidence: 99%

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

100

View full text Add to dashboard Cite

Abstract.The linear-quadratic model (LQ model) provides a biologically plausible and experimentally established method to quantitatively describe the dose-response to irradiation in terms of clonogenic survival. In the basic LQ formula, the clonogenic surviving fraction S d ̸S 0 following a radiation dose d (Gy) is described by an inverse exponential approximation:, wherein α and β are experimentally derived parameters for the linear and quadratic terms, respectively. Radiation is often combined with other agents to achieve radiosensitisation. In this study, we reviewed radiation enhancement ratios of hyperthermia (HT), halogenated pyrimidines (HPs), various cytostatic drugs and poly(ADP-ribose) polymerase-1 (PARP1) inhibitors expressed in the parameters α and β derived from cell survival curves of various mammalian cell cultures. A significant change in the α/β ratio is of direct clinical interest for the selection of optimal fractionation schedules in radiation oncology, influencing the dose per fraction, dose fractionation and dose rate in combined treatments. The α/β ratio may increase by a mutually independent increase of α or decrease of β. The results demonstrated that the different agents increased the values of both α and β. However, depending on culture conditions, both parameters can also be separately influenced. Moreover, it appeared that radiosensitisation was more effective in radioresistant cell lines than in radiosensitive cell lines. Furthermore, radiosensitisation is also dependent on the cell cycle stage, such as the plateau or exponentially growing phase, as well as on post-treatment plating conditions. The LQ model provides a useful tool in the quantification of the effects of radiosensitising agents. These insights will help optimize fractionation schedules in multimodality treatments.

show abstract

“…Here, both approaches could be used: a reduced radiotherapy dose, promoted by hyperthermia using the complex TER factor [81][82][83]. Different review articles have summarized the sensitizing effect on classical ionizing radiation by hyperthermia [80,[84][85][86]. Considerable success has been presented for hyperthermia in combination with radiotherapy for deep-seated tumors [87,, and success has also been observed in shallow tumors .…”

Section: Introduction and Interpretation Of A Relative "Old Method" Imentioning

confidence: 99%

“…Its characterization was introduced by the Thermal Enhancement Ratio (TER) [80], which measures the efficacy of the treatment. Hyperthermia, however, speeds up cellular metabolism, while possibly accentuating hypoxia, which works in an opposite manner; it reduces the efficacy of radiotherapy.…”

Section: Introduction and Interpretation Of A Relative "Old Method" Imentioning

confidence: 99%

What is on the Horizon for Hyperthermic Cancer Therapy?

GyP¹,

Dy²,

Hegyi³

2017

J Tradi Med Clin Natur

View full text Add to dashboard Cite

Low dose reirradiation in combination with hyperthermia: A palliative treatment for patients with breast cancer recurring in previously irradiated areas

Cited by 72 publications

References 24 publications

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

What is on the Horizon for Hyperthermic Cancer Therapy?

Contact Info

Product

Resources

About